H. Vergin et al., ANALYSIS OF METABOLITES - A NEW APPROACH TO BIOEQUIVALENCE STUDIES OFSPIRONOLACTONE FORMULATIONS, International journal of clinical pharmacology and therapeutics, 35(8), 1997, pp. 334-340
The aldosterone antagonist spironolactone undergoes extensive and comp
lex biotransformation. For investigation of bioequivalence of 2 oral s
pironolactone formulations, Spironolacton 50 Heumann and Aldactone 50,
the pharmacokinetics and bioequivalence of the parent drug and 2 pred
ominant active metabolites, canrenone and 7 alpha-thiomethylspirolacto
ne, were determined in a 2-way crossover study in 24 young healthy mal
e volunteers after multiple oral dosing of 100 mg once daily, Plasma s
amples were measured by a newly developed HPLC assay and individual ph
armacokinetic parameters of the 3 compounds were calculated by use of
noncompartmental techniques, Statistical analysis was performed by ANO
VA and nonparametric methods, Spironolactone was rapidly cleared from
plasma. Therefore, only C-ss,C-max and t(ss,max) were determined. Conc
erning C-ss,C-max bioequivalence was found with 90% classical shortest
confidence interval ranging from 80.7 - 112.4%. The intrasubject vari
ability for C-ss,C-max was determined to be 28.1%, Higher and persisti
ng concentrations were observed for the metabolites, For canrenone 90%
classical shortest confidence intervals were calculated as 95.4 - 105
.0% for AUC(ss,tau) as 92.9 - 105.8% for C-ss,C-max, and as 89.1 - 106
.3% for peak trough fluctuation (PTF). In the case of 7 alpha-thiometh
ylspirolactone the values were 84.2 - 103.0% for AUC(ss,tau). 77.0 - 9
8.6% for C-ss,C-max, and 85.0 - 100.4% for PTF. For t(ss,max) nonparam
etric 90% confidence intervals were determined as 0.00 to 1.50 h for s
pironolactone and canrenone and as -0.50 to 1.00 h for 7 alpha-thiomet
hylspirolactone, The intraindividual variability was below 30% for all
pharmacokinetic parameters in the case of the metabolites. Thus, bioe
quivalence of the test and the reference formulation can be concluded.
The study suggests the inclusion of parent compound and metabolites f
or bioequivalence testing of spironolactone formulations. Intraindivid
ual subject variability was clearly diminished by investigating bioequ
ivalence under steady-state conditions.